通过NPY在假阴性123 I-MIBG光阴学假阴性123的乳红细胞瘤中增加catecholamine分泌
Clinical nuclear medicine
|March 28, 2024
概括
神经Y (NPY) 在染细胞瘤 (PCC) 中的上调调节可能会通过增加北上腺素分泌而导致123I-meta-iodobenzylguanidine (MIBG) 扫描呈假阴性. 这一发现有助于解释PCC中的MIBG吸收变化.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 123I-MIBG是一种功能性成像工具,用于分泌甲醇胺的瘤.
- 在某些侵略性瘤类型中观察到减少MIBG吸收,但潜在的机制尚不清楚.
研究的目的:
- 为了确定影响MIBG积累在染色细胞瘤 (PCCs) 中的基因.
- 研究MIBG阴性PCC背后的分子机制.
主要方法:
- 在27个PCC样本 (MIBG阴性和MIBG阳性) 上进行RNA测序和RT-qPCR.
- 对初级PCC细胞培养物的分析.
主要成果:
- 9%的研究PCC是MIBG阴性.
- 神经Y (NPY) 在MIBG阴性PCC中显著增加.
- 在细胞培养中,NPY刺激了上腺素的分泌,而MIBG阴性PCC是上腺素的过分分泌.
结论:
- 在PCC中NPY的升级可能会增强catecholamine的分泌.
- 增加的NPY驱动的分泌与假阴性123I-MIBG光谱检测结果有关.
相关概念视频
Adrenergic Neurons: Neurotransmission
3.7K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Myasthenia Gravis: Diagnostic Tests
819
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
819
Adrenergic Agonists: Therapeutic Uses
770
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
770
Adrenergic Agonists: Direct-Acting Agents
1.5K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.5K


